In the LUAD tissue microarray cohort, high SEC61G protein expression was significantly associated with several adverse clinical characteristics, including advanced patient age (P = 0.013), T stage (P < 0.001), M stage (P < 0.001), and the number of lymph node metastases (P = 0.013) (Table S2). Here, SEC61G is linked to metastatic malignant neoplasm in the lymph nodes.